Contaminated Nelfinavir Does Not Increase Cancer Risk, EMEA Concludes
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Contaminated Nelfinavir Does Not Increase Cancer Risk, EMEA Concludes

LONDON -- July 24, 2008 -- Following a review of a number of toxicology studies, the European Medicines Agency (EMEA) confirms that there is no increased risk of developing cancer for patients who have taken nelfinavir (Viracept) contaminated with ethyl mesilate.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) requested a number of toxicology studies to better assess the potential harm to patients using nelfinavir contaminated with ethyl mesilate.

The studies showed that it is possible to calculate a threshold value below which ethyl mesilate does not cause any mutations in the DNA. The CHMP noted that patients or children born to mothers who had taken contaminated nelfinavir were exposed to ethyl mesilate levels well below this threshold and that, therefore, there was no increased risk of developing cancer for these patients compared with those patients who were not exposed to the contaminant.

The Committee therefore concluded that there was no need to monitor patients who had been exposed to high levels of contaminated nelfinavir through specific patient registries.

SOURCE: The European Medicines Agency

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities